MacroGenics, Inc. (MGNX)

Market Cap	173.23M
Revenue (ttm)	141.33M
Net Income (ttm)	-97.62M
Shares Out	62.76M
EPS (ttm)	-1.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	597,260
Open	2.920
Previous Close	2.880
Day's Range	2.760 - 2.930
52-Week Range	2.340 - 21.880
Beta	2.01
Analysts	Hold
Price Target	7.17 (+159.78%)
Earnings Date	Mar 6, 2025

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibod...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 10, 2013
• Employees: 339
• Stock Exchange: NASDAQ
• Ticker Symbol: MGNX
• Website: https://www.macrogenics.com

Financial Performance

In 2023, MacroGenics's revenue was $58.75 million, a decrease of -61.33% compared to the previous year's $151.94 million. Losses were -$9.06 million, -92.44% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for MGNX stock is "Hold." The 12-month stock price forecast is $7.17, which is an increase of 159.78% from the latest price.

Price Target

$7.17

(159.78% upside)

Analyst Consensus: Hold